

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/68	A2	(11) International Publication Number: WO 98/48048 (43) International Publication Date: 29 October 1998 (29.10.98)
<p>(21) International Application Number: PCT/GB98/01138</p> <p>(22) International Filing Date: 20 April 1998 (20.04.98)</p> <p>(30) Priority Data: 9707996.6 21 April 1997 (21.04.97) GB</p> <p>(71) Applicant (for all designated States except US): CAMBRIDGE UNIVERSITY TECHNICAL SERVICES LTD. (GB/GB); The Old Schools, Trinity Lane, Cambridge CB2 1TS (GB).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): BALASUBRAMANIAN, Shankar (GB/GB); University of Cambridge, Dept. of Chemistry, Lensfield Road, Cambridge CB2 1EW (GB).</p> <p>(74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
<p>(54) Title: DNA MUTATION MAPPING BY MULTIPLE ENERGY TRANSFER INTERACTIONS</p> <div data-bbox="611 1656 1550 1970"> </div> <p>(57) Abstract</p> <p>A method for determining the presence and location of a mismatch in a target sequence using Fluorescence Resonance Energy Transfer (FRET). The method comprises contacting the target sequence with at least three labelled oligonucleotide probes capable of hybridising to the natural sequence, in juxtaposition. The central probe is labelled with a donor fluorophore and the probe either side of this is labelled with a distinct acceptor fluorophore. Hybridisation to the target sequence results in resonance between the donor fluorophore and the acceptor fluorophores. A mismatch present in the target sequence will disrupt hybridisation to that region, resulting in a significant alteration to the resonance signal.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LY	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DNA MUTATION MAPPING BY MULTIPLE
ENERGY TRANSFER INTERACTIONS

Field of Invention

This invention relates to DNA mismatch screening,
5 especially using FRET-detected hybridisation.

Background of the Invention

There is a general increase in the exploration of gene
sequences and function. This has generated a need for new
approaches to nucleic acid analysis.

10 One of the simplest methods for detecting gene
sequences is to make use of the specific hybridisation
reaction between the target sequence and a suitable probe.

Recently, the use of Fluorescence Resonance Energy
Transfer (FRET) has been applied to the detection of
15 hybridised probes. Tyagi et al., Nature Biotech. (1996)
14:303-308, describe the use of FRET to distinguish between
hybridised and unhybridised probes in a homogeneous assay.
The probes each comprise a stem-and-loop structure with the
stem formed by the annealing of two complementary arm
20 sequences either side of the probe sequence. A fluorescent
moiety is attached to one arm and a non-fluorescent
quenching moiety is attached to the other arm. Separation
of the stem structure occurs on hybridisation of the probe
to the complementary target sequence. This separates the
25 two moieties and allows fluorescence to occur.

Summary of Invention

This invention is based on a realisation of the
utility of FRET as a technique for mapping point mutations
on a single strand of DNA.

30 According to the present invention, a method for
determining the presence of a mismatch in a target
sequence, comprises contacting the target sequence with
first, second and third oligonucleotides capable of
hybridising to the natural sequence, in juxtaposition,
35 wherein the oligonucleotides are respectively labelled with
first, second and third markers having first, second and
third absorption wavelengths and first, second and third

emission wavelengths such that there is resonance between either or each of first and second markers and between second and third markers, and observing the presence or absence of each or either resonance.

5 Description of the Drawings

The accompanying drawings are for the purpose of illustration only. In the drawings:

Fig. 1 is a schematic representation of the interaction of labelled oligonucleotides and target
10 sequence in a screening method embodying the invention;

Fig. 2 is a schematic representation of a more specific embodiment of the invention and represents another arrangement of the labels; and

Fig. 3 illustrates the different emission intensities
15 obtained when point mutations are present in the target sequence, using the arrangement of fluorophores shown in Fig. 2.

Description of Invention

The ability to monitor the interactions between
20 nucleic acids is achieved through the detection of sensitised acceptor emission, due to FRET between a donor fluorophore and two different acceptor fluorophores on associating strands. The absence of any of the components induced by a single base mismatch should cause a detectable
25 loss in sensitised acceptor emission.

The system illustrated in Fig. 1 comprises a target strand and three adjacent complementary oligonucleotides, A, B and C. These are typically each 8-13 base pairs in length. A and B are modified at the 5' end with a
30 fluorescein moiety (F). B and C are modified at the 3' end with two distinct types of acceptor fluorophore (X and Y) having different emission maxima and absorption profiles which overlap with the emission profile of fluorescein.

When no mismatches are present, all three
35 oligonucleotides will be bound to the target strand. Thus, when the system is excited at the absorption wavelength of fluorescein (488 nm), FRET will occur and the fluorescence

spectrum will show a decrease in the fluorescein emission relative to each singly-bound probe and appearance of two maxima due to secondary emissions from X and Y. In cases where a mismatch exists somewhere within the target sequence, the region in which the error occurs can be distinguished simply by analysing the fluorescence spectrum. If the mismatch lies within the binding domain of oligonucleotide A, no duplex will form in this region and the secondary emission from X will be lost. Similarly, for mismatches within the B region, the signals from X and Y will disappear, and for errors in region C, the Y emission will be absent.

Fig. 2 illustrates a different arrangement of the fluorophores. Again, three oligonucleotides are used. The central oligonucleotide is labelled with a donor fluorophore, 5'-carboxyfluorescein (fluorescein) only. The two adjacent oligonucleotides are each labelled with an individual acceptor fluorophore, 5'-carboxytetramethylrhodamine (TMR) and 5'-carboxyrhodamine-X (ROX). These fluorophores have absorption spectra which overlap with fluorescein's emission spectrum and have well separated emission maxima.

On binding of all three oligonucleotides, the fluorophores are positioned such that excitation of fluorescein results in energy transfer from fluorescein to both TMR and ROX. This transfer can again be monitored by observing the emission of the two acceptor fluorophores. Since the acceptors emit at two distinct wavelengths, introduction of a single base mismatch should be detectable by a loss in either or both of these signals.

The positioning of the fluorophores on each oligonucleotide required to optimise energy transfer can be easily determined by the skilled person by preliminary studies. The fluorophores will typically be separated, e.g. by a distance of 7 bases.

FRET assays can be carried out using a fluorimager, irradiating the assays with a laser at a suitable

wavelength, e.g. 488 nm for fluorescein, and scanning the emissions using suitable filters, e.g. 530 nm for fluorescein, 570 nm for TMR and 610 nm for ROX.

5 A characteristic of the common, donor fluorophore is that it should emit at a wavelength that is capable of exciting each of the acceptor fluorophores. The emission of each acceptor fluorophore must be resolvable.

10 An example of a common fluorophore that can be used as a donor is carboxyfluorescein. Additional examples of suitable acceptors include N,N,N',N'-tetramethyl-6-carboxyrhodamine and 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein.

15 The probes may be of DNA. Alternatively, and on the same principle, fluorescently-labelled DNA mimics, e.g. PNA, phosphorothioate DNA, could be used as the probes.

20 By the use of additional fluorophores with distinct emission profiles, it may be possible to extend this system for the screening of longer target sequences using multiple short complementary strands. This arrangement may permit screening of a section of the DNA target gene in a single homogeneous assay by excitation with, e.g. a fixed wavelength laser, or a fluorescence spectrometer, and instantly generating an emission spectrum which characterises where, if anywhere, there is a point mutation
25 or damage. It is envisaged that sequences of diagnostic oligonucleotides may be chosen to generate diagnostic kits for screening regions of mutational "hotspots".

30 The following Example illustrates the invention. In particular, it shows the ability to detect and locate point mutations in a target oligonucleotide.

Example

Four target oligonucleotides (SEQ ID Nos 1-4) were designed, each differing only in one nucleotide.

	SEQ ID No 1	5'CGTTCTAAGGATTACGTCGAACCTTTG3'
35	SEQ ID No 2	5'CGTTCAAAGGATTACGTCGAACCTTTG3'
	SEQ ID No 3	5'CGTTCTAAGGATAACGTCGAACCTTTG3'
	SEQ ID No 4	5'CGTTCTAAGGATTACGTCGAACCATTTG3'

Using oligo SEQ ID No 1 as the control, three oligonucleotide probes (SEQ ID No. 5-7) were designed, each capable of hybridising to a distinct region on the control.

5 SEQ ID No 5 3'GCAAGAT^{*}TTC5'
 SEQ ID No 6 3'CTAAT^{*}GCAG5'
 SEQ ID No 7 3'CT^{*}TGGAAAC5'

10

The probes were labelled with a fluorophore at the positions marked (*) as follows: probe SEQ ID No 5 with ROX; probe SEQ ID No 6 with fluorescein; and probe SEQ ID No 7 with TMR.

15

The emission intensity for both ROX and TMR-labelled probes increased significantly (relative to each singly-bound probe) on hybridisation to the control. However, as shown in Fig. 3, on reaction with each of the target oligonucleotides SEQ ID Nos 2-4, the emission intensity
20 varied significantly, depending on the position of the single nucleotide difference from the control.

20

This assay provides a simple method for the analysis of hybridisation events in solution and enables detection of mutations within defined regions of a target strand from
25 a single fluorescence measurement. The assay may be modified to utilise immobilised target or probes.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Cambridge University Technical Services Ltd.
- (B) STREET: The Old Schools, Trinity Lane
- (C) CITY: Cambridge
- (D) STATE: N/A
- (E) COUNTRY: United Kingdom
- (F) POSTAL CODE (ZIP): CB2 1TS

(ii) TITLE OF INVENTION: DNA MUTATION MAPPING BY MULTIPLE ENERGY
TRANSFER INTERACTIONS

(iii) NUMBER OF SEQUENCES: 7

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: WO Not yet known

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CGTTCTAAGG ATTACGTCGA ACCTTTG

27

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "Oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CGTTCAAGG ATTACGTCGA ACCTTTG

27

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CGTTCTAAGG ATAACGTCGA ACCATTG

27

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 27 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

CGTTCTAAGG ATTACGTCGA ACCATTG

27

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

GCAAGATTC

9

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

CTAATGCAG

9

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 9 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

- (A) DESCRIPTION: /desc = "Oligonucleotide"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:


CTTGGAAC

9

CLAIMS

1. A method for determining the presence and location of a mismatch in a target sequence, which comprises contacting the target sequence with first, second and third
5 oligonucleotides capable of hybridising to the natural sequence, in juxtaposition, wherein the oligonucleotides are respectively labelled with first, second and third markers capable of absorption at first, second and third wavelengths and emission at first, second and third
10 wavelengths, such that there is resonance between either or each of first and second markers and between second and third markers, and observing the presence or absence of resonance.
2. A method according to claim 1, wherein the second
15 oligonucleotide comprises two second markers resonating with the first and third markers respectively.
3. A method according to claim 1 or claim 2, wherein one or more markers is a fluorescent moiety.
4. A method according to any preceding claim, wherein the
20 one or more markers are selected from 5'-carboxyrhodamine-X, 5'-carboxytetramethylrhodamine, N,N,N',N'-tetramethyl-6-carboxyrhodamine, 2',7'-dimethoxy-4',5'-dichloro-6-carboxyfluorescein and 5'-carboxyfluorescein.
5. A method according to any preceding claim, wherein the
25 oligonucleotides each comprise 8-13 bases.
6. A method according to any preceding claim, wherein adjacent markers are separated by at least 7 bases.
7. A method according to any preceding claim, wherein the target or the first, second and third oligonucleotides are
30 immobilised.
8. A kit comprising, in separate compartments, first, second and third markers defined in any of claims 1 to 5.

FIG. 1



2/2

FIG. 2




FIG. 3

